Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05814549 · ClinicalTrials.gov registry record

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

A clinical trial of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
9
Enrollment target
7
Study locations

NCT05814549: Active study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT05814549 is a study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 189-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05814549, a study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
9 participants
Enrollment target
7
Study locations

Study Summary

The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test to test for HPV DNA will help detect HPV-related Oropharyngeal Cancer/OPC.

Interventions

  • DIAGNOSTIC_TEST NavDx

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2023-03-31
Est. Completion 2031-03-31

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT05814549

The ClinicalTrials.gov registry entry for NCT05814549 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which NavDx is the first listed.

NCT05814549 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05814549 about?

NCT05814549 is a clinical study titled "A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)". The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test...

What is the current status of trial NCT05814549?

This trial is currently active not recruiting. The enrollment target is 9 participants. The study started on 2023-03-31. Estimated completion is 2031-03-31.

What conditions does trial NCT05814549 study?

This clinical trial studies the following conditions: Oropharyngeal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma.

What interventions are being tested in trial NCT05814549?

The interventions under investigation include: NavDx (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05814549?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05814549 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Oropharyngeal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.